# Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT02560753** · PHASE1,PHASE2 · COMPLETED · sponsor: **T3D Therapeutics, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** T3D-959

## Key facts

- **NCT ID:** NCT02560753
- **Lead sponsor:** T3D Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-05-30
- **Final completion:** 2016-06-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560753, "Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02560753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*